Investor Relations

About Us

PAVmed is a medical device company employing a business model to bring innovative products from concept to commercialization with speed and capital efficiency, while enhancing and accelerating value creation.

PAVmed is building a deep pipeline of products encompassing a broad spectrum of clinical areas possessing attractive regulatory pathways and market opportunities currently exceeding $4 billion.  The company currently has five lead products to provide multiple near-term value creation opportunities

The Company is led by a team of accomplished medical device entrepreneurs. The leadership team has previously successfully implemented its unique business model of creating value with modest capital investment in four single-product companies, each of which rapidly advanced towards commercialization. Two of these four products have been cleared and commercialized, while two products are currently undergoing FDA review. PAVmed leverages this unique business model.

By establishing a long-term multi-product company with access to public capital, the company plans to build an expanding pipeline of innovative products across a range of specialties and clinical conditions.

Recent Press Releases

  • 11/28/17 8:00 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced that it has filed a 510(k) premarket notification submission with the U.S. Food and Drug Administration (FDA) for its CarpX™ minimally invasive device designed to treat carpal tunnel syndrome. “We are very excited to have reached this most important milestone in PAVmed’s corporate history,” said Lishan Aklog, M.D., PAVmed’smore...
  • 11/15/17 7:30 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multiproduct medical device company, today announced financial results for the three and nine months ended September 30, 2017 and provided a business update. Management Commentary “During this quarter and in recent weeks, PAVmed has continued its inexorable march towards important developmental, regulatory and commercialization milestones,” said Lishan Aklog, M.more...
  • 11/9/17 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (NASDAQ:PAVM; PAVMW), a highly differentiated, multi-product medical device company, today announced that the Company will host a conference call on Thursday, November 16, 2017 at 4:30 p.m. Eastern time. During this call Lishan Aklog, M.D., the Company’s Chairman and Chief Executive Officer, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, themore...

In the News

  • Forbes
    11/7/16 5:13 pm EST

    Shares of small-capitalization companies have been busy beavers, besting larger-cap stocks since February after a long period of under-performance, with the Russell 2000 outscoring the S&P 500-stock index. And analysts point out that small-cap investing has proven to be the better play for the long term.

SEC Filings

Click Here to view PAVmed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation

PROXY MATERIALS

Click Here to view the Proxy Statement for PAVmed Inc 2017 Annual Meeting

Click Here to view the Annual Report for PAVmed Inc 2017 Annual Meeting